These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15731572)

  • 1. EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.
    Chang KL; Lau SK
    Adv Anat Pathol; 2005 Mar; 12(2):47-52. PubMed ID: 15731572
    [No Abstract]   [Full Text] [Related]  

  • 2. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.
    Douillard JY; Ostoros G; Cobo M; Ciuleanu T; Cole R; McWalter G; Walker J; Dearden S; Webster A; Milenkova T; McCormack R
    J Thorac Oncol; 2014 Sep; 9(9):1345-53. PubMed ID: 25122430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clairvoyance or reliable prediction of the future?
    van Zandwijk N; van de Vijver MJ
    Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
    Ichihara E; Hotta K; Takigawa N; Kudo K; Kato Y; Honda Y; Hayakawa H; Minami D; Sato A; Tabata M; Tanimoto M; Kiura K
    Lung Cancer; 2013 Sep; 81(3):435-439. PubMed ID: 23809059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].
    Qiao J; Chen W
    Zhongguo Fei Ai Za Zhi; 2011 Oct; 14(10):806-10. PubMed ID: 22008111
    [No Abstract]   [Full Text] [Related]  

  • 6. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
    Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
    [No Abstract]   [Full Text] [Related]  

  • 7. Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
    Jänne PA
    Am J Respir Crit Care Med; 2008 Oct; 178(8):783-5. PubMed ID: 18832554
    [No Abstract]   [Full Text] [Related]  

  • 8. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.
    Pallis AG; Voutsina A; Kalikaki A; Souglakos J; Briasoulis E; Murray S; Koutsopoulos A; Tripaki M; Stathopoulos E; Mavroudis D; Georgoulias V
    Br J Cancer; 2007 Dec; 97(11):1560-6. PubMed ID: 18000506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized medicine and inhibition of EGFR signaling in lung cancer.
    Gazdar AF
    N Engl J Med; 2009 Sep; 361(10):1018-20. PubMed ID: 19692681
    [No Abstract]   [Full Text] [Related]  

  • 10. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE; Ramalingam SS
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract]   [Full Text] [Related]  

  • 11. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.
    Uramoto H; Sugio K; Oyama T; Ono K; Sugaya M; Yoshimatsu T; Hanagiri T; Morita M; Yasumoto K
    Lung Cancer; 2006 Jan; 51(1):71-7. PubMed ID: 16198442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
    Sequist LV; Joshi VA; Jänne PA; Muzikansky A; Fidias P; Meyerson M; Haber DA; Kucherlapati R; Johnson BE; Lynch TJ
    Oncologist; 2007 Jan; 12(1):90-8. PubMed ID: 17285735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.
    Hishida T; Nagai K; Mitsudomi T; Yokoi K; Kondo H; Horinouchi H; Akiyama H; Nagayasu T; Tsuboi M;
    J Thorac Cardiovasc Surg; 2010 Nov; 140(5):e69-71. PubMed ID: 20674944
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
    Zou B; Lee VHF; Yan H
    BMC Bioinformatics; 2018 Mar; 19(1):88. PubMed ID: 29514601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
    Lindahl KH; Sørensen FB; Jonstrup SP; Olsen KE; Loeschke S
    APMIS; 2015 Apr; 123(4):289-97. PubMed ID: 25556929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
    Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
    Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
    Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.